A5018049175- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Kruppel-like factors research
- Eosinophilic Disorders and Syndromes
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Hemoglobinopathies and Related Disorders
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Ubiquitin and proteasome pathways
- Synthesis and bioactivity of alkaloids
- HIV/AIDS drug development and treatment
- Malaria Research and Control
- Peripheral Neuropathies and Disorders
- Hematological disorders and diagnostics
- Cancer therapeutics and mechanisms
- Medicine and Dermatology Studies History
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Dupuytren's Contracture and Treatments
Hospital Universitari Germans Trias i Pujol
2021-2025
Hospital Del Mar
2014-2024
Institut Català d'Oncologia
2019-2024
Duran i Reynals Hospital
2022-2024
Universitat Autònoma de Barcelona
2014-2019
Josep Carreras Leukaemia Research Institute
2019
Hospital del Mar Research Institute
2017-2019
Vall d'Hebron Institute of Oncology
2018
Vall d'Hebron Hospital Universitari
2018
Vall d'Hebron Institut de Recerca
2018
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there limited real-world evidence. Here we evaluated the efficacy safety of KRd in RRMM treated following standard clinical practice hospitals Catalan region. This was retrospective, observational study. The objective response rate (ORR) according to IMWG criteria primary endpoint. Secondary endpoints included progression-free...
The presence of circulating plasma cells in patients with multiple myeloma is considered a marker for highly proliferative disease. In the study herein, impact assessed by cytology on survival was analyzed. Wright-Giemsa stained peripheral blood smears 482 newly diagnosed or cell leukemia were reviewed and classified into 4 categories according to percentage cells: 0%, 1–4%, 5–20%, following frequencies: 382 (79.2%), 83 (17.2%), 12 (2.5%) 5 (1.0%), respectively. Median overall group 47, 50,...
Abstract Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, anti-CD38 antibody) have limited treatment options there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in RRMM patients the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from were merged into single model compared using...
Summary Bone marrow histology is included in the diagnostic criteria of myeloproliferative neoplasms ( MPN s). However, some concerns have emerged about its reproducibility. To evaluate accuracy and to assess correlation with presence mutations clinical outcomes, two pathologists reviewed bone biopsies corresponding 211 patients . Despite low agreement evaluation individual histopathological characteristics, concordance among when establishing diagnosis was good (Kappa index 0·67). The...
The JAK2V617F allele burden has been identified as a risk factor for vascular events and myelofibrotic transformation in polycythemia vera (PV) essential thrombocythemia (ET). However, all previous studies have evaluated single time point measurement. Therefore, the frequency clinical significance of changes mutant load occurring during disease evolution remain unknown. In present study, monitoring was performed follow-up 347 patients (PV = 163, ET 184). According to their evolutionary...
Summary Low serum erythropoietin ( EPO ) is a minor criterion of Polycythaemia Vera PV but its diagnostic usefulness relies on studies performed before the discovery JAK 2 V617F mutation. The objective present study was to evaluate accuracy and allele burden as markers well combination different criteria in 287 patients (99 with , 137 Essential Thrombocythaemia 51 non‐clonal erythrocytosis). showed good marker for area under curve AUC chemiluminescent‐enhanced enzyme immunoassay CEIA being...
Summary The influence of driver mutations on leukaemic transformation was analysed in 1747 patients with polycythaemia vera or essential thrombocythaemia. With a median follow‐up 7·2 years, 349 died and 62 progressed to acute leukaemia myelodysplastic syndrome. Taking death as competing risk, CALR genotype associated lower risk [subdistribution hazard ratio (SHR): 0·13, 95% confidence interval (CI): 0·2–0·9, P = 0·039], whereas JAK2 V617F showed borderline significance for higher (SHR: 2·05,...
Analysis of the T cell receptor (TR) repertoire chronic lymphocytic leukemia-like monoclonal B lymphocytosis (CLL-like MBL) and early stage CLL is relevant for understanding dynamic interaction expanded clones with bystander cells. Here we profiled β chain (TRB) CD4+ CD8+ fractions from 16 CLL-like MBL 13 untreated, Binet A/Rai 0 patients using subcloning analysis followed by Sanger sequencing. The subpopulations both harbored restricted TRB gene repertoire, clonal expansions whose frequency...
ABSTRACT Background Acute kidney injury (AKI) in patients with multiple myeloma (MM) requiring renal replacement treatment (RRT) is associated high morbidity and mortality. Early reduction of serum free light chains (FLC) using both targeted therapy against MM intensive hemodialysis (IHD) may improve outcomes. We evaluated the effectiveness two different RRT techniques on recovery an patient population: standard dialysis procedure vs IHD either polymethylmethacrylate (PMMA) or...
e13a2 and e14a2 are the most frequent transcript types of BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) order discontinue TKI treatment remain so-called treatment-free remission (TFR) phase, but biological factors associated these goals not well established. This study aimed determine effect type on TFR patients receiving frontline imatinib (IM) or second-generation...
Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated incidence risk factors vascular complications 1613 patients from Spanish Myelofibrosis Registry. Over a total 6981 patient-years at risk, 6.4% study population had least one thrombotic event after MF diagnosis, amounting an rate 1.65 per 100 patient-years. Prior history thrombosis, JAK2 mutation, intermediate-2/high-risk International...
Abstract Objectives Clonal dominance is characteristic of patients with post‐polycythemia vera myelofibrosis (post‐PV MF), whereas in chronic phase usually display polyclonal hematopoiesis. The aim this work was to study the mutational burden JAK 2 V617F at progenitor level PV and correlate it evolutive disease presence mutations genes different V617F. Methods measured stem cells, granulocytes 45 (early n = 26, late 10, post‐PV MF 9). In addition, screening TET , DNMT 3A ASXL 1 SF 3B1 SRSF...
Oral anticancer drugs (OAD) are increasingly integrated into the care of patients (pts) with cancer since last twenty years. Recognition and management pharmacokinetic/pharmacodynamic drug-drug interactions (DDI) is critical to provide efficacious safe chronic treatments (CT) We aimed gain insight real-world prevalence potentially significant DDI between OAD CT potential consequences on their efficacy toxicities. Prospective observational study in an oncohematological hospital Oct 2020 – Feb...
<title>Abstract</title> Hydroxyurea (HU) constitutes the first-line treatment in most patients with essential thrombocythemia (ET), but criteria for changing therapy are not clearly established. The prognostic value of complete hematological response (CHR) and resistance/intolerance to HU was assessed 1080 from Spanish Registry ET, classified according revised IPSET-Thrombosis stratification (Very low- n = 61, Low- 83, Intermediate- 261, High-risk 675). With a median duration 5 years, CHR...